Brain targeting with docosahexaenoic acid as a prospective therapy for neurodegenerative diseases and its passage across blood brain barrier
- PMID: 32014503
- DOI: 10.1016/j.biochi.2020.01.013
Brain targeting with docosahexaenoic acid as a prospective therapy for neurodegenerative diseases and its passage across blood brain barrier
Abstract
Docosahexaenoic acid (DHA, 22:6n-3) is the main omega-3 polyunsaturated fatty acid in brain tissues necessary for common brain growth and function. DHA can be provided to the body through two origins: an exogenous origin, from direct dietary intakes and an endogenous one, from the bioconversion of the essential α-linolenic acid (ALA, 18:3n-3) in the liver. In humans, the biosynthesis of DHA from its precursor ALA is very low. A reduction in the cerebral amount of DHA is detected in patients suffering from neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Considering the vital functions of DHA for the brain, new methodologies to target the brain with DHA offers encouraging perceptions in the improvement of precautionary and therapeutic approaches for neurodegenerative diseases. The aim of the present review was to provide better understanding of the cerebral uptake of DHA in different form including free fatty acids, Lysophosphatidylcholines LysoPC-DHA as well as structured phospholipids. First, we explored the special structure of the blood-brain barrier BBB, BBB being a physical and metabolic barrier with restrictive properties. Then, we discussed the incorporation of DHA into the membrane phospholipids of the brain, the neuroprotective and therapeutic effect of DHA for neurological diseases.
Keywords: Blood-brain barrier; Docosahexaenoic acid; Lysophosphatidylcholine; Structured phospholipids.
Copyright © 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.
Similar articles
-
Emerging Role of Phospholipids and Lysophospholipids for Improving Brain Docosahexaenoic Acid as Potential Preventive and Therapeutic Strategies for Neurological Diseases.Int J Mol Sci. 2022 Apr 2;23(7):3969. doi: 10.3390/ijms23073969. Int J Mol Sci. 2022. PMID: 35409331 Free PMC article. Review.
-
Mechanisms of DHA transport to the brain and potential therapy to neurodegenerative diseases.Biochimie. 2016 Nov;130:163-167. doi: 10.1016/j.biochi.2016.07.011. Epub 2016 Aug 2. Biochimie. 2016. PMID: 27496085 Review.
-
Structured form of DHA prevents neurodegenerative disorders: A better insight into the pathophysiology and the mechanism of DHA transport to the brain.Nutr Res. 2021 Jan;85:119-134. doi: 10.1016/j.nutres.2020.12.003. Epub 2020 Dec 4. Nutr Res. 2021. PMID: 33482601 Review.
-
Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels.J Neurochem. 2018 Jul;146(2):186-197. doi: 10.1111/jnc.14342. J Neurochem. 2018. PMID: 29582413
-
The effects of dietary alpha-linolenic acid compared with docosahexaenoic acid on brain, retina, liver, and heart in the guinea pig.Lipids. 1999 May;34(5):475-82. doi: 10.1007/s11745-999-0387-3. Lipids. 1999. PMID: 10380119
Cited by
-
Why Have the Benefits of DHA Not Been Borne Out in the Treatment and Prevention of Alzheimer's Disease? A Narrative Review Focused on DHA Metabolism and Adipose Tissue.Int J Mol Sci. 2021 Oct 31;22(21):11826. doi: 10.3390/ijms222111826. Int J Mol Sci. 2021. PMID: 34769257 Free PMC article. Review.
-
Chemical Characterization and Beneficial Effects of Walnut Oil on a Drosophila melanogaster Model of Parkinson's Disease.Molecules. 2024 Sep 4;29(17):4190. doi: 10.3390/molecules29174190. Molecules. 2024. PMID: 39275038 Free PMC article.
-
Emerging Role of Phospholipids and Lysophospholipids for Improving Brain Docosahexaenoic Acid as Potential Preventive and Therapeutic Strategies for Neurological Diseases.Int J Mol Sci. 2022 Apr 2;23(7):3969. doi: 10.3390/ijms23073969. Int J Mol Sci. 2022. PMID: 35409331 Free PMC article. Review.
-
Investigation of Lysophospholipids-DHA transport across an in vitro human model of blood brain barrier.Heliyon. 2024 Oct 2;10(19):e38871. doi: 10.1016/j.heliyon.2024.e38871. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39421371 Free PMC article.
-
Spinocerebellar ataxia 38: structure-function analysis shows ELOVL5 G230V is proteotoxic, conformationally altered and a mutational hotspot.Hum Genet. 2023 Aug;142(8):1055-1076. doi: 10.1007/s00439-023-02572-y. Epub 2023 May 18. Hum Genet. 2023. PMID: 37199746 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical